SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2012-08-20** | Period of Report: **2012-08-15** SEC Accession No. 0001144204-12-047134

(HTML Version on secdatabase.com)

ISSUER

BioDrain Medical, Inc.

CIK:1446159| IRS No.: 331007393 | State of Incorp.:MN | Fiscal Year End: 1231 SIC: 3842 Orthopedic, prosthetic & surgical appliances & supplies

Mailing Address 2060 CENTRE POINTE BOULEVARD SUITE 7 MENDOTA HEIGHTS MN 55120

Business Address 2060 CENTRE POINTE BOULEVARD SUITE 7 MENDOTA HEIGHTS MN 55120 (612) 850-9460

REPORTING OWNER

SOK Partners LLC

CIK:1546490| State of Incorp.:NJ | Fiscal Year End: 1231 Type: 4 | Act: 34 | File No.: 000-54361 | Film No.: 121045560 Mailing Address 122 WILLOW STREET BROOKLYN NY 11217 Business Address 445 EAST BROAD STREET WESTFIELD NJ 07090 718-624-6277

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number:	3235-0287									
Expires:	02/28/2011									
Estimated average burden										
hours per response	0.5									

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of SOK Partners LI			2. Issuer Name and Ticker or Trading Symbol BioDrain Medical, Inc. [BIOR]	Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/15/2012	Officer (give title below) Other (specify below)				
122 WILLOW STR	EET							
BROOKLYN, NY 1	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)	Individual or Joint/Group Filing				
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	2. Transaction Date (Month/ Day/Year)		Transaction Code (Instr.		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v		(A) or (D)	Price	Reported	or Indirect (I) (Instr. 4)	
Common Stock, par value \$0.01 per share	08/15/2012		<u>J</u> (1) (2)		13,250,000	A	(1) (2)	22,480,770	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	or Exercise Price of Derivative	3. Transaction Date (Month/ Day/Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		Securities Underlying		of Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned	Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Sec	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			Direct (D) or Indirect (I) (Instr. 4)	
Convertible Promissory Grid Note	(<u>3</u>)	08/15/2012		<u>J</u> (1) (2)		21,262,234 (4)		(<u>3</u>)	(<u>3</u>)	Common Stock, par value \$0.01 per share	27,098,925	(1) (2)	1	D	

Explanation of Responses:

- 1. On August 15, 2012, the Issuer entered into a letter agreement (the "Forbearance Agreement") with SOK Partners, LLC ("SOK Partners") and Dr. Herschkowitz (both on his own behalf and on behalf of Atlantic Partners Alliance LLC ("Atlantic Partners")) and pursuant to which SOK Partners and Dr. Herschkowitz agreed to (i) forbear from enforcing their rights under the Convertible Promissory Note (the "First Note"), dated December 20, 2011, in the original principal amount of \$240,000 made by the Issuer in favor of Dr. Herschkowitz and the Convertible Promissory Grid Note (the "Grid Note"), dated March 28, 2012, made by the Issuer in favor of SOK Partners LLC ("SOK Partners"),
- 2. (ii) terminate the letter agreement, dated March 14, 2012, between the Issuer and Atlantic Partners, which granted Dr. Herschkowitz and his affiliates certain anti-dilution rights, and (iii) extend the maturity date of each of the First Note and the Grid Note to December 31, 2012. In consideration of such agreements, the Issuer agreed to (x) issue to each of Dr. Herschkowitz and SOK Partners on the date of the Forbearance Agreement 13,250,000 shares of the Issuer's Common Stock, par value \$0.01 per share ("Shares") and (y) adjust the conversion price under each of the First Note and the Grid Note from \$0.065 per Share to \$0.014 per Share.
- 3. The Grid Note may be converted at any time into a number of Shares equal to the then outstanding principal amount and accrued interest under the Grid Note divided by \$0.014. The current outstanding principal amount and accrued interest under the Grid Note is \$379,384.95, which amount, if converted into Shares, would result in

the issuance of 27,098,925 Shares. The conversion price under the First Note is subject to adjustment upon the occurrence of certain events, such as stock splits and the issuance of stock for a consideration per Share less than such conversion price.

4. The adjustment of the conversion price under the Grid Note from \$0.065 to \$0.014 would result, upon conversion of the outstanding principal amount and accrued interest under the Grid Note into Shares, in the issuance of 21,262,234 additional Shares to SOK Partners.

Signatures

SOK PARTNERS, LLC, By Atlantic Partners Alliance LLC, its sole member /s/ Samuel Herschkowitz

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.